---
title: "APGE.US (APGE.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/APGE.US/news.md"
symbol: "APGE.US"
name: "APGE.US"
parent: "https://longbridge.com/en/quote/APGE.US.md"
datetime: "2026-03-17T03:57:37.971Z"
locales:
  - [en](https://longbridge.com/en/quote/APGE.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/APGE.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/APGE.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/APGE.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/APGE.US/news.md)


# APGE.US (APGE.US) — Related News

### [Apogee Therapeutics CEO Sells 20,000 Shares](https://longbridge.com/en/news/279101905.md)
*2026-03-14T00:10:00.000Z*
> Michael Thomas Henderson, CEO of Apogee Therapeutics, sold 20,000 shares of common stock on March 11, 2026, under a Rule

### [Apogee Therapeutics: Strong Phase II AD Data and 2026 Readouts Underpin Buy Rating and Potential to Displace JAK-Based Regimens](https://longbridge.com/en/news/278568437.md)
*2026-03-10T13:45:25.000Z*
> TD Cowen analyst Tyler Van Buren has maintained a Buy rating on Apogee Therapeutics (APGE) stock, citing strong Phase II

### [Blank Chcke Co, Apogee Acquisition Corp Files For IPO Of Up To $250 Million - SEC Filing](https://longbridge.com/en/news/278171981.md)
*2026-03-06T21:54:40.000Z*
### [Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference](https://longbridge.com/en/news/277770942.md)
*2026-03-04T11:34:24.000Z*
> Apogee Therapeutics (NASDAQ:APGE) presented key clinical milestones at the TD Cowen Healthcare Conference, focusing on d

### [RBC Capital Reaffirms Their Hold Rating on Apogee Therapeutics (APGE)](https://longbridge.com/en/news/277620157.md)
*2026-03-03T12:26:35.000Z*
> RBC Capital analyst Brian Abrahams has reaffirmed a Hold rating on Apogee Therapeutics (APGE) with a price target of $82

### [Key facts: Apogee Therapeutics posts $285.6M loss; plans Phase 3 trial](https://longbridge.com/en/news/277513451.md)
*2026-03-02T20:04:21.000Z*
> Apogee Therapeutics posted an operational loss of $285.6 million while heavily investing in its antibody pipeline, featu

### [Craig-Hallum Sticks to Their Buy Rating for Apogee Therapeutics (APGE)](https://longbridge.com/en/news/277492684.md)
*2026-03-02T15:45:54.000Z*
> Craig-Hallum analyst Adam Vogel has maintained a Buy rating on Apogee Therapeutics (APGE) with a price target of $116.00

### [Apogee Therapeutics (NASDAQ:APGE) Releases Earnings Results, Beats Expectations By $0.02 EPS](https://longbridge.com/en/news/277465797.md)
*2026-03-02T12:47:10.000Z*
> Apogee Therapeutics (NASDAQ:APGE) reported quarterly earnings of ($1.03) per share, exceeding expectations by $0.02. The

### [Dyne Therapeutics 2025 10-K: $0 Revenue, Net Loss $446.2M](https://longbridge.com/en/news/277463042.md)
*2026-03-02T12:25:01.000Z*
> Dyne Therapeutics reported no product revenue for 2025, with a net loss of $446.2 million and an operating loss of $468.

### [Apogee Therapeutic | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/277462456.md)
*2026-03-02T12:23:37.000Z*